to develop a Covid-19 vaccine candidate that could be produced using the existing influenza virus vaccine manufacturing facilities | Pandemic PACT Tracker

Key facts

Disease
COVID-19
start year
2020
Known Financial Commitments (USD)
$615,250
Funder
Gates Foundation
Principal Investigator
N/A
Research Location
United States of America
Lead Research Institution
PATH
Research Priority Alignment
N/A

Research Category
Vaccines research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Not applicable
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:42 minutes ago

View all publications at Europe PMC

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.

Differential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjects.

Humoral and cellular immune responses to CoronaVac up to one year after vaccination.

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.